These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20564079)

  • 41. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imatinib (Glivec) and gastrointestinal stromal tumours in Nigerians.
    Durosinmi MA; Salawu L; Lawal OO; Ojo OS; Alatishe OI; Oyekunle AA; Bolarinwa RA; Adisa AO; Badmos K; Anomneze EE; Ayansanwo AO
    Afr J Med Med Sci; 2013 Dec; 42(4):325-32. PubMed ID: 24839736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.
    Yardley DA; Burris HA; Markus T; Spigel DR; Greco FA; Mainwaring M; Waterhouse DM; Webb CD; Hainsworth JD
    Clin Breast Cancer; 2009 Nov; 9(4):237-42. PubMed ID: 19933079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis.
    Chen P; Zong L; Zhao W; Shi L
    World J Gastroenterol; 2010 Sep; 16(33):4227-32. PubMed ID: 20806443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
    Ryu MH; Lee JL; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
    Jpn J Clin Oncol; 2006 Jan; 36(1):17-24. PubMed ID: 16418188
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo.
    Palmberg E; Johnsen JI; Paulsson J; Gleissman H; Wickström M; Edgren M; Ostman A; Kogner P; Lindskog M
    Int J Cancer; 2009 Mar; 124(5):1227-34. PubMed ID: 19058199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
    Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy evaluation of imatinib in the treatment of patients with gastrointestinal stromal tumors.
    Zong L; Chen P; Zhao W; Shi L
    Turk J Gastroenterol; 2011 Oct; 22(5):479-85. PubMed ID: 22234754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.
    Yim E; An HJ; Cho U; Kim Y; Kim SH; Choi YG; Shim BY
    Korean J Intern Med; 2018 Mar; 33(2):432-434. PubMed ID: 27384439
    [No Abstract]   [Full Text] [Related]  

  • 52. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
    Pishvaian MJ; Slack R; Koh EY; Beumer JH; Hartley ML; Cotarla I; Deeken J; He AR; Hwang J; Malik S; Firozvi K; Liu M; Elston B; Strychor S; Egorin MJ; Marshall JL
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):843-53. PubMed ID: 23014737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.
    Bompas E; Velay B; Blay JY
    Leuk Lymphoma; 2004 Nov; 45(11):2353-4. PubMed ID: 15512830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose escalation of imatinib after failure of standard dose in Korean patients with metastatic or unresectable gastrointestinal stromal tumor.
    Park I; Ryu MH; Sym SJ; Lee SS; Jang G; Kim TW; Chang HM; Lee JL; Lee H; Kang YK
    Jpn J Clin Oncol; 2009 Feb; 39(2):105-10. PubMed ID: 19052040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography.
    Prenen H; Deroose C; Vermaelen P; Sciot R; Debiec-Rychter M; Stroobants S; Mortelmans L; Schöffski P; Van Oosterom A
    Anticancer Res; 2006; 26(2A):1247-52. PubMed ID: 16619531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
    Floris G; Wozniak A; Sciot R; Li H; Friedman L; Van Looy T; Wellens J; Vermaelen P; Deroose CM; Fletcher JA; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2013 Feb; 19(3):620-30. PubMed ID: 23231951
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.
    Bauer S; Hilger RA; Mühlenberg T; Grabellus F; Nagarajah J; Hoiczyk M; Reichardt A; Ahrens M; Reichardt P; Grunewald S; Scheulen ME; Pustowka A; Bock E; Schuler M; Pink D
    Br J Cancer; 2014 Mar; 110(5):1155-62. PubMed ID: 24434430
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor.
    Kelly CM; Shoushtari AN; Qin LX; D'Angelo SP; Dickson MA; Gounder MM; Keohan ML; Mcfadyen C; Sjoberg A; Singer S; DeMatteo RP; Hwang S; Heinemann MH; Francis JH; Antonescu CR; Chi P; Tap WD
    Invest New Drugs; 2019 Apr; 37(2):282-290. PubMed ID: 30101387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy.
    Nikfarjam M; Kimchi E; Shereef S; Gusani NJ; Jiang Y; Liang J; Sehmbey M; Staveley-O'Carroll KF
    J Gastrointest Surg; 2008 Nov; 12(11):2023-31. PubMed ID: 18546049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.